Journals

2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000


2014

Ciaranello AL, Leroy V, Rusibamayila A, Freedberg KA, Shapiro R, Engelsmann B, Lockman S, Kelly KA, Dabis F, Walensky RP. Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival. A IDS.2014 Jul;28 Suppl 3:S287-99. Link

Doherty K, Essajee S, Penazzato M, Holmes C, Resch S, Ciaranello A. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res. 2014 May 2;14:201. Link

McCormick AW, Abuelezam NN, Rhode ER, Hou T, Walensky RP, Pei PP, Becker JE, DiLorenzo MA, Losina E, Freedberg KA, Lipsitch M, Seage GR 3rd. Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One. 2014 May 27;9(5):e98272. Link

Kaplan R, Caldwell J, Middelkoop K, Bekker LG, Wood R. Impact of ART on TB Case Fatality Stratified by CD4 Count for HIV-Positive TB Patients in Cape Town, South Africa (2009-2011). J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):487-94. Link

Richardson ET, Morrow CD, Kalil DB, Bekker LG, Wood R. Shared air: a renewed focus on ventilation for the prevention of tuberculosis transmission. PLoS One. 2014 May 7;9(5):e96334. Link

Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: A model-based analysis in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2014 Apr 11. [Epub ahead of print] Link

Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS. 2014 Jan 28;28(3):365-76. Link

Tsai AC, Fricchione GL, Walensky RP, Ng C, Bangsberg DR, Kerry VB. Global Health Training in US Graduate Psychiatric Education. Acad Psychiatry. 2014 Mar 25. [Epub ahead of print] Link

Andrews JR, Morrow C, Walensky RP, Wood R. Integrating Social Contact and Environmental Data in Evaluating Tuberculosis Transmission in a South African Township. J Infect Dis. 2014 Apr 28. [Epub ahead of print] Link

Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, Walensky RP, Freedberg KA, Bassett IV. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014 Feb 26;14:110. Link

Desmonde S, Essanin JB, Aka AE, Messou E, Amorissani-Folquet M, Rondeau V, Ciaranello A, Leroy V. Morbidity and health care resource utilization in HIV-infected children after antiretroviral therapy initiation in Côte d'Ivoire, 2004-2009. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e95-103. Link

Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, Paltiel AD, Wood R, Walensky RP, Losina E, Bekker LG, Freedberg KA. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One. 2014 Jan 22;9(1):e85197. Link

Ciaranello A, Lu Z, Ayaya S, Losina E, Musick B, Vreeman R, Freedberg KA, Abrams EJ, Dillabaugh L, Doherty K, Ssali J, Yiannoutsos CT, Wools-Kaloustian K. Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) east Africa regional analysis. Pediatr Infect Dis J. 2014 Jun;33(6):623-9. Link


2013

Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One. 2013 Dec 18;8(12):e84173. Link

Kerry VB, Walensky RP, Tsai AC, Bergmark RW, Bergmark BA, Rouse C, Bangsberg DR. US medical specialty global health training and the global burden of disease. J Glob Health. 2013 Dec;3(2):020406. Link

Ciaranello AL, Morris BL, Walensky RP, Weinstein MC, Ayaya S, Doherty K, Leroy V, Hou T, Desmonde S, Lu Z, Noubary F, Patel K, Ramirez-Avila L, Losina E, Seage GR 3rd, Freedberg KA. Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS One. 2013 Dec 13;8(12):e83389. Link

April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, Freedberg KA, Walensky RP. The survival benefits of antiretroviral therapy in South Africa. J Infect Dis. 2014 Feb 15;209(4):491-9. Link

Bassett IV, Regan S, Luthuli P, Mbonambi H, Bearnot B, Pendleton A, Robine M, Mukuvisi D, Thulare H, Walensky RP, Freedberg KA, Losina E, Mhlongo B. Linkage to care following community-based mobile HIV testing compared with clinic-based testing in Umlazi Township, Durban, South Africa. HIV Med. 2014 Jul;15(6):367-72. Link

Govindasamy D, Kranzer K, van Schaik N, Noubary F, Wood R, Walensky RP, Freedberg KA, Bassett IV, Bekker LG. Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. PLoS One. 2013 Nov 13;8(11):e80017. Link

Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR 3rd, Cohen MS, Freedberg KA. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31;369(18):1715-25. Link

Hung KJ, Tsai AC, Johnson TR, Walensky RP, Bangsberg DR, Kerry VB. Scope of global health training in U.S. obstetrics and gynecology residency programs. Obstet Gynecol. 2013 Nov;122(5):1101-9. Link

Hyle EP, Sax PE, Walensky RP. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med. 2013 Oct 14;173(18):1746-8. Link

Kerkhoff AD, Wood R, Lowe DM, Vogt M, Lawn SD. Blood neutrophil counts in HIV-infected patients with pulmonary tuberculosis: association with sputum mycobacterial load. PLoS One. 2013 Jul 9;8(7):e67956. Link

Gupta-Wright A, Wood R, Bekker LG, Lawn SD. Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service. J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):261-70. Link

Gupta RK, Lawn SD, Bekker LG, Caldwell J, Kaplan R, Wood R. Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa. Int J Tuberc Lung Dis. 2013 Aug;17(8):1014-22. Link

Messou E, Chaix ML, Gabillard D, Yapo V, Toni TD, Minga A, Kouakou MG, Ouattara E, Rouzioux C, Danel C, Eholie SP, Anglaret X. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):211-9. Link

Andrews JR, Lawn SD, Dowdy DW, Walensky RP. Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. Clin Infect Dis. 2013 Oct;57(7):1021-6. Link

Pathai S, Lawn SD, Gilbert CE, McGuinness D, McGlynn L, Weiss HA, Port J, Christ T, Barclay K, Wood R, Bekker LG, Shiels PG.Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study. AIDS. 2013 Sep 24;27(15):2375-84. Link

Doherty K, Ciaranello A. What is needed to eliminate new pediatric HIV infections: the contribution of model-based analyses.Curr Opin HIV AIDS. 2013 Sep;8(5):457-66. Link

Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, Swaminathan S, Flanigan TP, Walensky RP, Freedberg KA. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS One. 2013 May 31;8(5):e64604. Link

Ramirez-Avila L, Noubary F, Pansegrouw D, Sithole S, Giddy J, Losina E, Walensky RP, Bassett IV. The acceptability and feasibility of routine pediatric HIV testing in an outpatient clinic in Durban, South Africa. Pediatr Infect Dis J. 2013 Dec;32(12):1348-53. Link

Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. Int J Tuberc Lung Dis. 2013 May;17(5):636-43. Link

Nglazi MD, Kaplan R, Orrell C, Myer L, Wood R, Bekker LG, Lawn SD. Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression. PLoS One. 2013;8(3):e57907. Link

Andrews JR, Morrow C, Wood R. Modeling the role of public transportation in sustaining tuberculosis transmission in South Africa. Am J Epidemiol. 2013 Mar 15;177(6):556-61. Link

Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824. Link

IeDEA Pediatric Working Group. A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africa--the International epidemiologic Databases to Evaluate AIDS (IeDEA). J Int AIDS Soc. 2013 Jan 15;16(1):17998. Link

Sax PE. Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis. 2013 May;56(9):1344-6. Link

Orrell C, Levison J, Ciaranello A, Bekker LG, Kuritzkes DR, Freedberg KA, Wood R. Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy. Pediatr Infect Dis J. 2013 Jun;32(6):644-7. Link

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group.Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. Link

Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther. 2013;18(3):399-408. Link

Desmonde S, Coffie PA, Aka EA, Amani-Bosse C, Messou E, Dabis F, Ciaranello A, Leroy V. Health care resource utilization in untreated HIV-infected children in a pediatric programme, Abidjan, Côte d'Ivoire, 2004-2009. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):e14-21. Link

Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, Walensky RP. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis. 2013 Feb;56(4):587-97. Link

Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013 Feb 1;128(1-2):90-7. Link

Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholié S, Freedberg KA. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2013;18(1):45-55. Link

Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013; 158:84-92. Link

Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, Keatinge J, Park JE, Maruva M, Cerda R, Wood R, Dabis F, Freedberg KA. Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clin Infect Dis. 2013; 53:430-46. Link


2012

Levison J, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, Freedberg KA, Wood R. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance from a large HIV treatment program in South Africa. PLoS One. 2012; 7:e32144. Link

Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky PR. Genotype assays and third-line ART in resource-limited settings: A simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012; 26:1083-93.Link

Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, Walensky RP, Freedberg KA, Losina E. Loss to follow-up and mortality among HIV-infected people co-infected With TB at ART initiation in Durban, South Africa. JAIDS. 2012; 59:25-30.Link

Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials. 2012; 13:1-10.Link

Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR 3rd, Paltiel AD. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012; 54:1504-13Link

Anglaret X, Scott C, Walensky RP, Outtara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholie S, Freedberg K. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2012; doi:10.3851/IMP2231 [Epub ahead of print].Link

Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012; 26:987-95Link

Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of Progression to Active Tuberculosis Following Reinfection With Mycobacterium tuberculosis. Clin Infect Dis. 2012 [Epub ahead of print] Link

Ahonkhai AA, Noubary F, Munro, A, Stark R, Wilke M, Freedberg KA, Wood R, Losina E. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012; 7:e32993.Link

Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute Hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012; 55:279-290.Link

Kranzer K, Govindasamy D, van Schaik N, Thebus E, Davies N, Zimmermann M, Jeneker S, Lawn S, Wood R, Bekker LG. Incentivized recruitment of a population sample to a mobile HIV testing service increases the yield of newly diagnosed cases, including those in need of antiretroviral therapy. HIV Med. 2012; 13:132-7. Link

Schackman BS, Metsch L, Colfax GN, Leff JA, Wong AY, Scott CA, Feaster DJ, Gooden L, Matheson T, Mandler R, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. Drug Alcohol Depend. 2012; Epub ahead of print.Link

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y, Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012; 26:45-56. Link

Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP. Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J Inf Dis. 2012; 206:543-51.Link

Arbelaez C, Wright EA, Losina E, Millen JC, Kimmel S, Dooley M, Reichmann WM, Mikulinsky R, Walensky RP. Emergency Provider Attitudes and Barriers to Universal HIV Testing in the Emergency Department. J Emerg Med. 2012; 42:7-14.Link

Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-Infected individuals in southern India: a trial-based analysis. PLoS One. 2012; 7:e36001. Link

Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012; 26:625-34.Link

Donnell-Fink LA, Arbelaez C, Collins JE, Novais A, Case A, Pisculli ML, Reichmann WM, Katz JN, Losina E, Walensky RP. Acceptability of fingerstick vs. oral fluid rapid HIV testing: results from the universal screening for HIV-infection in the emergency room (USHER-Phase II) randomized controlled trial. J Acquir Immune Defic Syndr. 2012; [Epub ahead of print].Link

Reichmann WM, Walensky RP, Case A, Novais A, Arbelaez C, et al. Estimation of the prevalence of undiagnosed and diagnosed HIV in an urban emergency department. PLoS One. 2012; 6:e27701. Link

Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, Lawn SD, Wood R, Bekker LG. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis. 2012; 12:21. Link

Ciaranello AL, Perez F, Keatinge J, Park J, Engelsmann B, Maruva M, Walensky RP, Dabis F, Chu J, Rusibamayila A, Mushavi A, Freedberg KA. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. Plos Med. 2012; 9:e1001156.Link

Hom JK, Wang B, Chetty S, Giddy J, Mazibuko M, Allen J, Walensky RP, Losina E, Freedberg KA, Bassett IV. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. PLoS One. 2012; 7:e43281. Link

Ramirez-Avila L, Regan S, Giddy J, Chetty S, Ross D, Katz JN, Freedberg KA, Walensky RP, Losina E, Bassett IV. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. 2012. AIDS Behav. Epub 2012.Link

Morrow C, Munro A, Wilke M, Stark R, Wood R. Remote sensing of HIV care programmes using centrally collected laboratory results: can we monitor ART programme effectiveness? S Afr Med J. 2012; 102:501-5.Link

Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, Walenskey RP. The Clinical and Economic Impact of Genotype Testing at First-line Antiretroviral Therapy Failure for HIV-infected Patients in South Africa. Clinical Infectious Diseases. 2012; doi: 10.1093/cid/cis887Link

Shenoy ES, Walensky RP, Lee H, Orcutt B, Hooper DC. Resource Burden Associated with Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: The Patient Access Managers' Perspective. Infect Control Hosp Epidemiol 2012; 33(8): 849-52. Link

Shenoy ES, Hsu H, Noubary F, Hooper DC, Walensky RP. National Survey of Infection Preventionists: Policies for Discontinuation of Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Infect Control Hosp Epidemiol 2012; 33(12): 1272-5. Link

Morrow C, Munro A, Wilke M, Stark R, Wood R. Remote sensing of HIV care programmes using centrally collected laboratory results: can we monitor ART programme effectiveness? S Afr Med J. 2012; 102:501-5.Link

Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; The ANRS 12222 Morbidity/Mortality Study Group. AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in Cote d'Ivoire. Clin Infect Dis. 2012; 54:714-72 Link


2011

April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med. 2011; 26:661-7 Link

Bassett I, Chetty S, Giddy J, Reddy S, Bishop K, Lu Z, Losina E, Freedberg K, Walensky R. Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med. 2011; 12:46-53 Link

Chu J, Sloan CE, Freedberg KA, Yazdanpanah Y, Losina E. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. AIDS Res Ther. 2011; 8:14 Link

Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP, CEPAC-International and OCTANE Investigators. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011; 25:479-92 Link

Ciaranello AL, Perez F, Maruva M, Chu J, Engelsmann B, Keatinge J, Walensky RP, Mushavi A, Mugwagwa R, Dabis F, Freedberg KA; CEPAC-International Investigators. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One. 2011; 6(6):e20224 Link

Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011; 9:59. Link

Hsu H, Rydzak C, Cotich K, Wang B, Sax P, Losina E, Freedberg K, Goldie S, Lu Z, Walensky R; for the CEPAC Investigators. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011; 12:97-108 Link

Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011; 18:506-12 Link

Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011; 56:356-64 Link

Messou E, Kouakou M, Gabillard D, Gouessé P, Koné M, Tchehy A, Losina E, Freedberg KA, Dri-Yoman TN, Anzian A, Toure S, Anglaret X. Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011; 1;57 Suppl 1:S34-9 Link

Pisculli ML, Reichmann WM, Losina E, Donnell-Fink LA, Arbelaez C, Katz JN, Walensky RP. Factors associated with refusal of rapid HIV testing in an emergency department. AIDS Behav. 2011 ; 15:734-42. Link

Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD, Cost-Effectiveness of Preventing AIDS Complications-International Investigators. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011; 56:26-35 Link

Wang B, Losina E, Stark R, Munro A, Walensky RP, Wilke M, Martin D, Lu Z, Freedberg KA, Wood R. Loss to follow-up in a community clinic in South Africa roles of gender, pregnancy and CD4 count. S Afr Med J. 2011; 101:253-257 Link


2010


Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky R, Freedberg K. Intensive Tuberculosis Screening for HIV-Infected Patients Ready to Start ART in Durban, South Africa. Clin Infect Dis., 2010; 51:823-829 Link

Bassett I, Regan S, Chetty S, Giddy J, Uhler L, Holst H, Ross D, Katz J, Walensky R, Freedberg KA, Losina E. Who starts ART Durban, South Africa?... not everyone who should. AIDS. 2010; 24 Suppl 1:S37-44. Link

Bassett IV, Walensky RP. Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S77-84. Link

Bender M, Kumarasamy N, Mayer K, Wang B, Walensky R, Flanigan T, Schackman B, Scott C, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010; 50:416-25. Link

Kimmel A, Weinstein M, Anglaret A, Goldie S, Losina E, Yazdanpanah Y, Messou E, Cotich K, Walensky R, Freedberg KA. Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness. J Acquir Immune Defic Syndr. 2010; 54:258-68 Link

Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2010 Jun 9. [Epub ahead of print] Link

Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, Ross D, Scott CA, Uhler LM, Katz JN, Holst H, Freedberg KA. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010; 5:e9538. Link

Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y. Economic evaluation of ART in resource-limited countries. Curr Opin HIV AIDS. 2010 May; 5:225-31. Link

Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, Losina E, Freedberg KA, Danel C, Anglaret X, Yazdanpanah Y. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One. 2010; 5:e13414 Link

Robbins G, Johnson K, Chang Y, Jackson K, Sax P, Meigs J, Freedberg KA. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010; 50:779-786. Link

Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B, Losina E, Freedberg KA, Weinstein MC, Goldie SJ, CEPAC Investigators. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010; 5: e12647 Link

Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA, Cepac US And Actg A5164 Investigators. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials. 2010; 11 :248-59

Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, Stoler AW, Lu Z, Walensky RP, Flanigan TP, Bender MA, Freedberg KA, Swaminathan S, CEPAC International investigators. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010; 5: e12747 Link

Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, CEPAC Investigators. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010; 51:392-400. Link

Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA, CEPAC-International Investigators. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010; 7:e1000382 Link

Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis. 2010 Jul 1; 51:85-92. Link

Walensky RP, Kuritzkes DR. The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. Clin Infect Dis. 2010 Jan 15; 50:272-5. Link

Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA; CEPAC-International Investigators. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther. 2010; 15:351-61. Link

Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010; 5:e13132 Link


2009

April MD, Walensky RP, Chang Y, et al. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr 2009;51:310-6. Link

Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009;51:135-9. Link

Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E, Walensky RP. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009; 49:1915-27. Link

Ciaranello AL, Walensky RP, Sax PE, Chang Y, Freedberg KA, Weissman JS. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials 2009;10:13-24. Link

Ganguli I, Bassett IV, Dong KL, Walensky RP. Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep. 2009 Nov;6(4):217-23.

Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009;49(10):1579-81. Link

Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA; ART-LINC Collaboration of International Epidemiological Databases to Evaluate AIDS (IeDEA); CEPAC International investigators. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med 2009 Oct;6(10):e1000173. Link

Linas BP, Losina E, Rockwell A, Walensky RP, Cranston K, Freedberg KA. Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr 2009;51:513-21. Link

Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009;14:523-31. Link

Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-15. Link

Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009;151:157-66. Link

2008

Bassett IV, Farel C, Szmuilowicz ED, Walensky RP. HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis 2008;47:695-701.

Bassett IV, Giddy J, Wang B, et al. Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med 2008;9:863-7.

Ciaranello AL, Seage GR, 3rd, Freedberg KA, Weinstein MC, Lockman S, Walensky RP. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS 2008;22:2359-69.

Jean-Jacques M, Walensky RP, Aaronson WH, Chang Y, Freedberg KA. Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care 2008;20:977-83.

Losina E, Figueroa P, Duncan J, et al. HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993 2005. Int J Infect Dis 2008;12:132-8.

Millen JC, Arbelaez C, Walensky RP. Implications and Impact of the New US Centers for Disease Control and Prevention HIV Testing Guidelines. Curr Infect Dis Rep 2008;10:157-63.

Ojikutu BO, Zheng H, Walensky RP, et al. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J 2008;98:204-8.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-33.

Valerio L, Yazdanpanah Y, Poizot-Martin I, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008;47:50-5.

Walensky RP, Freedberg KA, Weinstein MC. Monitoring of antiretroviral therapy in low-resource settings. Lancet 2008;372:288; author reply 9.

Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008;197:1324-32.

2007

Campos N, Salomon JA, Nunes MD, Samet J, Freedberg KA, Goldie SJ. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with human immunodeficiency virus. Am J Med 2007; 120:272-9

Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and care in the United States. Clin Infect Dis 2007; 45 Suppl4:S248-S254.

Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV regimen simplification: A simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45: 1062-70.

Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. Beyond short term virologic suppression, the long term benefits of genotypic resistance testing in patients with extensive prior antiretroviral: a model based approach. HIV Med 2007; 7: 439-50.

McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage III GR. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44: 1115-1122.

Wolf LL, Walensky RP. Testing for HIV infection in the United States. Current Inf Dis Rep 2007; 9: 76-82.

2006

Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19.

Liddicoat RV, Losina E, Kang M, Freedberg KA, Walensky RP. Refusing HIV testing in an urgent care setting: Results from the Think HIV program. AIDS Patient Care & STDs 2006; 20: 84-92.

Linas BP, Zheng H, Losina E, Walensky RP, Freedberg KA. Assessing the impact of federal HIV prevention spending on HIV testing and awareness. Am J Public Health 2006; 96: 1038-43.

Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanpanah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials 2006; 7: 59-69.

Linas BP, Zheng H, Losina E, Rockwell A, Walensky RP, Cranston K, Freedberg KA. Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis 2006;43:1357-64.

Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage III GR, Moore RD, Freedberg KA. The lifetime cost of current HIV care in the Unites States. Med Care 2006; 44: 990-997.

Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. J Acquir Immune Defic Syndr 2006; 43 (supplement 1): S113-118.

Liddicoat RV, Zheng H, Internicola J, Werner BG, Kazianis A, Golan Y, Rubinstein EP, Freedberg KA, Walensky RP. Implementing a Routine, Voluntary HIV Testing Program in a Massachusetts County Prison. J Urban Health 2006; 83: 1127-31.

Paltiel AD, Walensky RP, Schackman BR, Seage III GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: Effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145: 797-806.

Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Ann Intern Med 2006; 145: 459-62.

2005

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther 2005; 10:42-52.

Paltiel AD, Weinstein MC, Kimmel AD, Seage III GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded screening for HIV in the United States: An analysis of cost-effectiveness. N Engl J Med. 2005; 352:586-595.

Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr 2005; 38:163-173.

Samet JH, Horton NJ, Meli S, Dukes K, Tripp T, Sullivan L, Freedberg KA. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antiviral Therapy 2005; 10:83-93.

Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-1323.

Sax PE, Losina W, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-effectiveness of Enfuvirtide (ENF) in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005; 39:69-77.

Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid section 115 demonstrations for early HIV treatment in Georgia and Massachusetts. Health Care Financ Rev 2005; 26:67-80.

Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L, for the Center for Adherence Support and Evaluation (CASE) team. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care 2005; 17:927-937.

Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of screening dollars: The example of HIV counseling, testing and referral. Med Decis Making 2005; 25:321-329.

Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA. Routine HIV testing: An economic evaluation of current guidelines. Am J Med 2005; 118:292-300.

Walensky RP, Losina E, Malatesta L, Barton GE, O'Connor CA, Skolnik PR, Hall JM, McGuire JF, Freedberg KA. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Pub Health 2005; 95:71-3.

Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kimmel AD, Zhang H, N'Dri-Yoman T, Salamon R, Kaplan J, Freedberg K. Clinical impact and cost-effectiveness (C-E) of co-trimoxazole (CTX) prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308.

2004

Losina E, Islam R, Pollock AC, Sax PE, Freedberg KA, Walensky RP. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis 2004; 38:1613-1622.

Schackman BR, Oneda K, Goldie SJ. The cost-effectiveness of elective cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. AIDS 2004; 18:1827-1834.

Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? PharmacoEconomics 2004; 22:293-300

Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage III GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: How good is good enough? Vaccine 2004; 22:4044-4053.

Walensky RP, Freedberg KA, Losina E, Skolnik PR, Hall JM, Malatesta L, Barton GE, O'Connor CA, McGuire JF. Voluntary HIV testing as part of routine medical care - Massachusetts, 2002. MMWR 2004; 53:523-526.

.

2003

Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003; 115:632-641.

Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36:652-662.

Mrus JM, Yi MS, Freedberg KA, Wu AW, Zackin R, Gorski H, Tsevat J. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making 2003; 23:414-421.

Pincus JM, Crosby SS, Losina E, King ER, LaBelle C, Freedberg KA. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis 2003; 37:1699-1704.

Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis 2003; 36:86-96.

Yazdanpanah Y, Goldie SJ, Weinstein MC, Losina E, Lebrun T, Paltiel AD, Seage GR, 3rd, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2003;7:257-266.

2002

Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for HIV-related Pneumocystis carinii pneumonia (PCP): Using simulation modeling to inform clinical guidelines. Arch Intern Med 2002; 162:921-928.

Johri M, Paltiel AD, Goldie SJ, Freedberg KA. The cost-effectiveness of state AIDS Drug Assistance Programs: equity and efficiency in a fragmented financing system. Med Care 2002; 40:429-441.

Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162:2478-2486.

Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. A comparison of HIV/AIDS health state utilities using community and patient preference weights: Implications for cost-effectiveness analyses. Med Decis Making 2002; 22:27-38.

Seage GR, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA. The role of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts in chronic HIV-1 mortality. J Acquir Immune Defic Syndr 2002; 30:421-428.

Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, 3rd, Losina E, Zhang H, Islam R, Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr 2002; 31:27-37.

Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis 2002; 35:606-610.

Walensky RP, Losina E, Steger-Craven KA, Freedberg KA. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med 2002; 162:887-892.

Yazdanpanah Y, Goldie SJ, Weinstein MC, Losina E, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002; 7:257-266.

2001

Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DC, Zhang H, Kimmel AD, Goldie SJ. The cost-effectiveness of combination antiretroviral therapy in HIV. N Engl J Med 2001;344:824-31.

Includes editorial by Robert Steinbrook, MD

Freedberg KA, Losina E, Goldie SJ. The cost-effectiveness of antiretroviral therapy for HIV disease [letter]. N Engl J Med 2001; 345:68-69.

Freedberg KA, Sullivan LM, Georgakis A, Savetsky J, Stone V, Samet JH. Improving participation in HIV clinical trials: Impact of a brief intervention. HIV Clin Trials 2001; 2:205212.

Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285:3107-3115.

Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost-effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with human immunodeficiency virus. Am J Med 2001; 111:140-149.

Paltiel AD, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA. A pre-evaluation of clinical trial data: The case of pre-emptive CMV therapy in HIV. Clin Inf Dis 2001;32:783-93.

Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of improving access to early antiretroviral therapy among uninsured HIV-infected adults. Am J Publ Hlth 2001;91:1456-63.

Vidrih JA, Walensky RP, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med 2001; 111:192-94.

Walensky RP, Rosenberg ES, Ferraro MJ, Losina E, Walker B, Freedberg KA. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Inf Dis 2001; 33:570-72.

Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter J, Zhang H, Kimmel AD, Freedberg KA. Resistance testing to guide the choice of second-line therapy in HIV: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.

Includes editorial by Michael S. Saag, MD

Yazdanpanah Y, Chne, G, Losina E, Soldie SJ, Merchadou, LD, Alfandari S, Seage GR, Sullivan L, Marimoutou C, Paltiel AD, Salamon R, Mouton Y, Freedberg KA. Incidence of primary opportunistic infections in two HIV-infected French clinical cohorts. Int J Epi 2001;30:864-871.

2000

Gross PA, Asch S, Kitahata MM, Freedberg KA, Barr D, Melnick DA, Bozzette SA. Performance measures for guidelines on preventing opportunistic infections in HIV-infected patients. Clin Inf Dis 2000; 30:S85-93.

Kaplan JE, Masur H, Holmes KK, Freedberg KA, Holtgrave D, Piscitelli SC, Van Dyke R, Watts H, and the USPHS/IDSA Prevention of Opportunistic Infections Working Group. An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Inf Dis 2000; 30:S15-28.